LAPTM4B and gastric cancer: The LAPTM4B-35 expression rate was 30% in chronic gastritis with intestinal metaplasia, 55% in intestinal metaplasia beside cancer tissues, 60% in dysplasia, peaking at 90.4% in GC (Table 3).